SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jul 1, 2026

CTNM

Contineum Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago
Insider cluster: 2 insiders, $334K total
Actionable Insight • Neutral

The sales are routine and likely tax/option-exercise related. No bearish signal. Monitor for any upcoming news or earnings, but this cluster alone does not warrant action.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$15.10
T+0 close · Jul 1, 2026 · via day close
Latest settled
−17.28%
T+60 · $12.49
Vs SPY
−20.29%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 2 $15.10entry
  2. T+1 · 4mo ago +2.85%α +1.97% · $15.53
  3. T+5 · 4mo ago +2.32%α +1.39% · $15.45
  4. T+20 · 4mo ago +4.30%α +4.72% · $15.75
  5. T+60 · 7w ago −17.28%α −20.29% · $12.49
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Carmine Stengone and CMO Tim Watkins sold small open-market positions on June 30, 2026, totaling $334K (0.05% of market cap). The sales coincide with derivative exercises, suggesting tax- or exercise-cost-related liquidity rather than a bearish signal. Director grants on June 26 are non-cash and routine.

Key Financial Metrics

Direction
selling
Total Value
$334.0K
Insiders
2

Key Facts

  • CEO Stengone sold 10,000 shares at $16.01 ($160K) on June 30, 2026
  • CMO Watkins sold 10,833 shares at $16.02 ($174K) on June 30, 2026
  • Both insiders exercised stock options on the same day, indicating cashless exercise/sale pattern
  • Total open-market sales of $334K represent ~0.05% of CTNM's $613M market cap
  • Seven directors received non-cash grants of 19,000 shares each on June 26, 2026

Financial Impact

Insider sales of $334K are trivial relative to $613M market cap; no material financial impact

insider ownershipdilution

Risk Factors

  • Insider sales could be misinterpreted as bearish by the market
  • Historical CTNM reports have underperformed, suggesting potential overreaction to similar filings

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CTNM-1782947128950

US Market Status

Market Closed · Opens in 7h

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 1, 2026